Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRI	IBER	PATIENT:			
Name:		Name:			
Ward:		NHI:			
Alectinib					
	ssment required after 6 months  isites (tick boxes where appropriate)  Patient has locally advanced, or metastatic, unresectable, non  There is documentation confirming that the patient has an ALF	-small cell lung cancer  K tyrosine kinase gene rearrangement using an appropriate ALK test			
CONTINUATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)  O No evidence of progressive disease according to RECIST criteria and The patient is benefitting from and tolerating treatment					

C:	D-1	
Signed.	Date:	
Oigilica.	 Duic.	